Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Fluticasone furoate (FF) Dry Powder Inhaler; Drug: Fluticasone propionate (FP) Dry Powder Inhaler; Drug: Budesonide (BUD) Turbuhaler; Drug: Placebo (ELLIPTA or DISKUS)
Sponsor: GlaxoSmithKline
Not yet recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Intervention: Device: anharmonic morphological analysis of the respiratory signals (AMARS)
Sponsor: University Hospital, Bordeaux
Recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Widespread Chronic Pain
Interventions: Drug: Ketotifen Fumarate; Drug: Placebo; Other: Standard of Care
Sponsors: McGill University Health Center; The Louise And Alan Edwards Foundation
Recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: COPD Asthma
Intervention:
Sponsor: Clalit Health Services
Recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Optimization of substituted imidazobenzodiazepines as novel asthma treatments.
Eur J Med Chem. 2016 Nov 24;126:550-560
Authors: Jahan R, Stephen MR, Forkuo GS, Kodali R, Guthrie ML, Nieman AN, Yuan NY, Zahn NM, Poe MM, Li G, Yu OB, Yocum GT, Emala CW, Stafford DC, Cook JM, Arnold LA
Abstract
We describe the synthesis of analogs of XHE-III-74, a selective ?4?3?2 GABAAR ligand, shown to relax airway smooth muscle ex vivo and reduce airway hyperresponsiveness in a murine asthma model. To improve properties of this compound as an asthma therapeutic, a series of analogs with a deuterated methoxy group in place of methoxy group at C-8 position was evaluated for isotope effects in preclinical assays; including microsomal stability, cytotoxicity, and sensorimotor impairment. The deuterated compounds were equally or more metabolically stable than the corresponding non-deuterated analogs and increased sensorimotor impairment was observed for some deuterated compounds. Thioesters were more cytotoxic in comparison to other carboxylic acid derivatives of this compound series. The most promising compound 16 identified from the in vitro screens also strongly inhibited smooth muscle constriction in ex vivo guinea pig tracheal rings. Smooth muscle relaxation, determined by reduction of airway hyperresponsiveness with a murine ovalbumin sensitized and challenged model, showed that 16 was efficacious at low methacholine concentrations. However, this effect was limited due to suboptimal pharmacokinetics of 16. Based on these findings, further analogs of XHE-III-74 will be investigated to improve in vivo metabolic stability while retaining the efficacy at lung tissues involved in asthma pathology.
PMID: 27915170 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Association of interleukin-18 and asthma.
Inflammation. 2016 Dec 02;
Authors: Xu MH, Yuan FL, Wang SJ, Xu HY, Li CW, Tong X
Abstract
Cytokine-mediated immunity plays a dominant role in the pathogenesis of various immune diseases, including asthma. The recent identification of the family interleukin (IL)-1-related cytokine IL-18 now contributes to our understanding of the fine-tuning of cellular immunity. IL-18 can act as a cofactor for Th2 cell development and IgE production and also plays an important role in the differentiation of Th1 cells. Recent work identified an IL-18 association with the pathogenesis of asthma, wherein increased IL-18 expression was found in the serum of patients. Furthermore, IL-18 polymorphisms with susceptibility to asthma were reported, suggesting that IL-18 may be therapeutically relevant to asthma. In this review, we discuss the role of IL-18 in the pathogenesis of asthma and its therapeutic potential based on current research.
PMID: 27913952 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Asthma
Interventions: Drug: Fp MDPI; Drug: FS MDPI; Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Severe Asthma
Intervention:
Sponsors: Academisch Medisch Centrum – Universiteit van Amsterdam (AMC-UvA); University Medical Center Groningen
Recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Association of Allergic Rhinitis and Sinusitis with Childhood Asthma.
Indian Pediatr. 2016 Nov 5;:
Authors: Kumar S, Singh M, Das RR, Mathew JL, Saxena AK
Abstract
BACKGROUND: To study the point prevalence of allergic rhinitis and sinusitis in childhood asthma and to examine the relationships among them.
METHODS: In 250 children (age <13 y) with mild-to-moderte asthma, allergic rhinitis was diagnosed by clinical plus nasal eosinophilia criteria, and sinusitis was diagnosed clinically plus confirmation by computerized tomography scan.
RESULTS: The point prevalence of allergic rhinitis was 13.6%, and of sinusitis was 2%. On multivariate analysis, allergic rhinitis, sinusitis, and family history were significantly associated with asthma severity.
CONCLUSION: Allergic rhinitis is common in childhood, but sinusitis is rare.
PMID: 27889716 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Idiopathic Angioedema
Interventions: Drug: Omalizumab; Drug: Placebos
Sponsors: University of Wisconsin, Madison; Novartis Pharmaceuticals
Not yet recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days